Note J - Equity-based Compensation - Stock Options, SARs and RSUs Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended
		Jun. 30, 2019		Mar. 31, 2019
Outstanding (in shares)		2,092
Outstanding, weighted average exercise price (in dollars per share)		$ 3.55
Outstanding, weighted average remaining contractual term (Year)	[1]	4 years 149 days	[2]	4 years 219 days
Options / SARs / RSUs cancelled/forfeited/expired (in shares)		(30)
Options / SARs / RSUs cancelled/forfeited/expired, weighted average exercise price (in dollars per share)		$ 1.04
Options / SARs exercised and RSUs vested (in shares)		(111)
Options / SARs exercised and RSUs vested, weighted average exercise price (in dollars per share)		$ 2.50
Outstanding (in shares)		1,951	[2]	2,092
Outstanding, weighted average exercise price (in dollars per share)		$ 3.64	[2]	$ 3.55
Outstanding, aggregate value	[2],[3],[4]	$ 20,915
Exercisable (in shares)	[5]	626
Exercisable, weighted average exercise price (in dollars per share)	[5]	$ 9.64
Exercisable, weighted average remaining contractual term (Year)	[1],[5]	4 years 116 days
Exercisable, aggregate value	[3],[4],[5]	$ 2,957
Stock Appreciation Rights (SARs) [Member]
Options granted (in shares)
Options granted (in dollars per share)
Non-option instruments granted (in shares)
Non-option instruments, weighted average exercise price (in dollars per share)
Restricted Stock Units (RSUs) [Member]
Non-option instruments granted (in shares)	[3],[4]
Non-option instruments, weighted average exercise price (in dollars per share)

[1] Calculation of weighted average remaining contractual term does not include RSUs that were granted, which have indefinite contractual term.

[2] Due to the ceiling imposed on the SAR grants, the outstanding amount above can be exercised for a maximum of 1,875 thousands shares of the Company's common stock as of June 30, 2019. SAR grants made on or after January 1, 2012 are convertible for a maximum number of shares of the Company's common stock equal to 50% of the SARs subject to the grant.

[3] Calculation of aggregate intrinsic value is based on the share price of the Company's common stock on June 30, 2019 ($14.36 per share).

[4] Represents an amount lower than $1.

[5] Due to the ceiling imposed on the SAR grants, the exercisable amount above can be exercised for a maximum of 588 thousands shares of the Company's common stock as of June 30, 2019.